Coming soon: AmoyDx® FGFR1-4 NGS Panel
Detection of mutations and fusions in the FGFR1, FGFR2, FGFR3 and FGFR4 genes
The soon available AmoyDx® FGFR1-4 NGS Panel (RUO) is an NGS assay for the qualitative detection of mutations (SNVs, InDels) and fusions in the FGFR1-4 genes on DNA and RNA from FFPE material. The panel covers the complete coding sequence of the four genes. As recommended in various publications (e.g. Lamarca, A. et al., 2023), the detection of FGFR gene fusions is carried out at the RNA level; unknown fusion partners can also be identified. The library is prepared using the hybrid capture method (ddCAP technology) with an optimized DNA/cDNA co-library preparation workflow, which mostly takes place in a single reaction tube.
As with all AmoyDx® NGS panels, the sequence data is analyzed locally using the AmoyDx® NGS Data Analysis System (ANDAS).
For further information, please contact us at molpath@zytomed-systems.de
1. Lamarca, A. et al. Futibatinib: second EMA approval for FGFR inhibitor in cholangiocarcinoma ESMO Open, Volume 8, Issue 6, 102049, 2023
Further topics
Out Now: AmoyDx® FGFR1-4 NGS Panel
Detection of mutations and fusions in the FGFR1, FGFR2, FGFR3 and FGFR4 genes
Product update: BRCA1 and BRCA2
The new AmoyDx® BRCA Pro Panel is an improved version of the AmoyDx® BRCA1 and BRCA2 Gene Mutation Detection Kit. Both kits enable analysis of the entire coding regions of the BRCA1 and BRCA2 genes, and of exon/ intron boundries in DNA from FFPE specimen and from peripheral whole blood.
